Projects per year
Abstract
Molecular imaging of the immune checkpoint receptor PD-1 and its ligand PD-L1 is increasingly investigated as a strategy to guide and monitor PD-1:PD-L1-targeted immune checkpoint therapy. We provide an overview of the current state-of-the-art on PD-1- and PD-L1-specific imaging agents for quantitative, real-time assessment of PD-1:PD-L1 expression in the tumor environment and discuss their potential for clinical translation.
| Original language | English |
|---|---|
| Pages (from-to) | 3559-3570 |
| Number of pages | 12 |
| Journal | Theranostics |
| Volume | 8 |
| Issue number | 13 |
| DOIs | |
| Publication status | Published - 7 Jun 2018 |
Keywords
- Biomarker
- Immunotherapy
- Molecular imaging
- PD-1:PD-L1
Fingerprint
Dive into the research topics of 'Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy: Embracing nuclear medicine for the benefit of personalized immunotherapy'. Together they form a unique fingerprint.Projects
- 6 Finished
-
ANI209: Nanobody-mediated Immune CHEchpoint imaging and inhibition (NICHE)
Breckpot, K. (Administrative Promotor) & Broos, K. (Collaborator)
1/01/19 → 7/10/19
Project: Fundamental
-
SRP48: Strategic Research Programme: Cancer Cell Targeting in Myeloma and Melanoma (MyMe)
Vanderkerken, K. (Administrative Promotor), Thielemans, K. (Administrative Promotor), Vanderkerken, K. (Co-Promotor) & Breckpot, K. (Co-Promotor)
1/11/17 → 31/10/24
Project: Fundamental
-
SRP47: Strategic Research Programme: Molecular Imaging and targeting of macrophages in Inflammation (ITARMI)
Lahoutte, T. (Administrative Promotor), Van Ginderachter, J. (Co-Promotor), Devoogdt, N. (Collaborator) & De Jonge, J. (Collaborator)
1/11/17 → 31/10/22
Project: Fundamental
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver